NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis $1.21 -0.05 (-3.97%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.03 (+2.07%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oragenics Stock (NYSE:OGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oragenics alerts:Sign Up Key Stats Today's Range$1.21▼$1.2950-Day Range$1.03▼$1.4652-Week Range$1.01▼$18.90Volume135,710 shsAverage Volume305,801 shsMarket Capitalization$4.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oragenics, Inc. is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics. The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications. Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN. Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.AI Generated. May Contain Errors. Read More Oragenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreOGEN MarketRank™: Oragenics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oragenics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oragenics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oragenics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOragenics has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.83% of the float of Oragenics has been sold short.Short Interest Ratio / Days to CoverOragenics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oragenics has recently increased by 78.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOragenics does not currently pay a dividend.Dividend GrowthOragenics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.83% of the float of Oragenics has been sold short.Short Interest Ratio / Days to CoverOragenics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oragenics has recently increased by 78.07%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News SentimentOragenics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.MarketBeat Follows2 people have added Oragenics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oragenics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Oragenics is held by insiders.Percentage Held by InstitutionsOnly 18.71% of the stock of Oragenics is held by institutions.Read more about Oragenics' insider trading history. Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGEN Stock News HeadlinesOragenics Appoints Natasha Giordano to Board of DirectorsSeptember 3, 2025 | msn.comOragenics Q2 2025 Shareholder UpdateAugust 11, 2025 | globenewswire.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).September 18 at 2:00 AM | Weiss Ratings (Ad)Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa TrialJuly 31, 2025 | finance.yahoo.comOragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical DevelopmentJuly 16, 2025 | globenewswire.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking AlphaJuly 3, 2025 | seekingalpha.comOragenics stock tumbles after announcing $20 million preferred stock offeringJuly 2, 2025 | investing.comOragenics Completes Approximately $16.5 Million OfferingJuly 2, 2025 | globenewswire.comSee More Headlines OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed this year? Oragenics' stock was trading at $11.0790 at the beginning of 2025. Since then, OGEN shares have decreased by 88.8% and is now trading at $1.24. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) issued its quarterly earnings data on Monday, August, 16th. The company reported ($54.00) EPS for the quarter, topping analysts' consensus estimates of ($72.00) by $18.00. When did Oragenics' stock split? Oragenics shares reverse split before market open on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Oragenics' major shareholders? Top institutional shareholders of Oragenics include Clear Street LLC (8.58%) and Bank of America Corp DE (1.89%). Insiders that own company stock include Fred Telling, Alan W Dunton and Robert C Koski. View institutional ownership trends. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Animal Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT). Company Calendar Last Earnings8/16/2021Today9/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGEN Previous SymbolNYSE:OGEN CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.66 million Net MarginsN/A Pretax Margin-243,950.00% Return on Equity-2,087.95% Return on Assets-486.56% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book2.07Miscellaneous Outstanding Shares4,127,000Free Float10,979,000Market Cap$5.20 million OptionableN/A Beta0.82 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:OGEN) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.